SCHEMBL4740564

SCHEMBL4740564

COc1ccc2[nH]nc(NS(=O)(=O)c3cccs3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 1/20 0.54
KMT2A Q03164 4/20 0.53
MAPT P10636 3/20 0.53
MEN1 O00255 3/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
HTT P42858 2/20 0.52
TNF P01375 1/20 0.52
LMNA P02545 1/20 0.52
NOD2 Q9HC29 1/20 0.52
NOD1 Q9Y239 1/20 0.52
FADS1 O60427 1/20 0.47
TTK P33981 1/20 0.47
CCR4 P51679 1/20 0.47
USP8 P40818 4/20 0.46
USP2 O75604 3/20 0.46
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6974524 0.78 TTK (0.45) SMN1; SMN2TP53KMT2AMAPTMEN1
SCHEMBL4739269 0.77 FADS1 (0.47) SMN1; SMN2KMT2AMAPTMEN1ALDH1A1
SCHEMBL4738870 0.77 FADS1 (0.55) KMT2AMAPTMEN1LMNAFADS1
SCHEMBL186027 0.76 ALDH1A1 (0.55) SMN1; SMN2TP53KMT2AMAPTMEN1
SCHEMBL7571540 0.74 SMN1; SMN2 (0.80) SMN1; SMN2TP53KMT2AMAPTMEN1
SCHEMBL4502466 0.73 GSK3B (0.53) SMN1; SMN2MAPTALDH1A1LMNATTK
SCHEMBL2654720 0.71 GRM4 (0.54) SMN1; SMN2TP53KMT2AMAPTMEN1
SCHEMBL11700238 0.70 FADS1 (0.58) KMT2AMAPTMEN1KDM4EALDH1A1
SCHEMBL1461052 0.69 TTK (0.76) KMT2AMEN1ALDH1A1TTK
SCHEMBL2307271 0.69 KMT2A (0.85) SMN1; SMN2KMT2AMAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO claimed
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC BUCK INST RES AGING (US) 2024-07-04 US disclosed
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders LEXICON PHARMACEUTICALS, INC. 2008-08-21 US disclosed
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer LEXICON PHARMACEUTICALS, INC. 2008-08-14 US disclosed
WO-2008089310-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed
WO-2008089307-A2 DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER LEXICON PHARMACEUTICALS, INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194557-A1 Methods and compositions for the treatment of pain, inflammation and cancer TNF, IL6, CXCL8 SMN1; SMN2 2636/4885TP53 446/4885KMT2A 3920/4885
US-20240216316-A1 DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC DAGLA, DAGLB, MGLL SMN1; SMN2 2796/4885TP53 151/4885KMT2A 2832/4885
US-20080200458-A1 Methods and compositions for the treatment of body composition disorders CPT1B, CPT1A, SHBG SMN1; SMN2 700/4885TP53 4636/4885KMT2A 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.